PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (GH), a leading precision oncology company, today announced new real-world data published in Current Medical Research and Opinion finding ...

Strategic collaboration to enable streamlined and accelerated access to Shield blood-based colorectal cancer screening test across Quest’s vast network Physicians nationwide now have the ability to ...

It’s good news in the fight against colorectal cancer: A new test can detect the disease with a simple blood draw. But don’t cancel your colonoscopy just yet — that old standby is still more reliable ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer screening (CRC) is now covered for active-duty service members and ...

A groundbreaking blood test for colorectal cancer screening has received approval from the U.S. Food and Drug Administration (FDA), offering the potential to revolutionize early detection for one of ...

Active-duty service members and eligible family members now have access to blood test for colorectal cancer screening with no copay Shield is the first and only blood test approved by the FDA as a ...